Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Brinzolamide

FDA-approved product (suspension/drops, ophthalmic), marketed as Azopt, Brinzolamide.

Registered studies
50+
Lab records
4
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Brinzolamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Glaucoma
  • Ocular hypertension
  • Open-angle glaucoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Carbonic anhydrase inhibitors
FDA pharmacologic class
Carbonic Anhydrase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA47.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis83.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 4 of 4 lab records
Open Brinzolamide in ChEMBL Registered studies below
Show the 4 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Brinzolamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Intravitreal Ranibizumab (Lucentis®) in the Treatment of Non-leaking Macular Cysts in Retinal Dystrophy

    NCT03763227 · start 2015-07-24

    Registered record
    Registry ID
    NCT03763227
    Conditions
    Retinal Dystrophies
    Interventions
    Intravitreal ranibizumab (IVR) injection; Carbonic Anhydrase Inhibitor (CAI) therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-07-24
    Completion
    2019-08-29
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRetinal Dystrophies
    InterventionIntravitreal ranibizumab (IVR) injection; Carbonic Anhydrase Inhibitor (CAI) therapy
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety of Brinzolamide/Brimonidine Fixed Combination BID Compared to Brinzolamide BID Plus Brimonidine BID in Subjects With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

    NCT02339584 · start 2015-04-14

    Registered record
    Registry ID
    NCT02339584
    Conditions
    Open-Angle Glaucoma; Ocular Hypertension
    Interventions
    Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension; Brinzolamide 10 mg/mL eye drops, suspension; Brimonidine 2 mg/mL eye drops, solution; Vehicle
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-04-14
    Completion
    2016-11-01
    Enrolment
    493

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-Angle Glaucoma; Ocular Hypertension
    InterventionBrinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension; Brinzolamide 10 mg/mL eye drops, suspension; Brimonidine 2 mg/mL eye drops, solution; Vehicle
    PhasePhase 3
    Registry statusCompleted

  • Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes

    NCT02512042 · start 2015-04

    Registered record
    Registry ID
    NCT02512042
    Conditions
    Glaucoma
    Interventions
    Test-Brinzolamide 1% Ophthalmic suspension; Reference-Brinzolamide 1% Ophthalmic suspension
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-04
    Completion
    2016-05
    Enrolment
    973

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionTest-Brinzolamide 1% Ophthalmic suspension; Reference-Brinzolamide 1% Ophthalmic suspension
    PhasePhase 3
    Registry statusCompleted

  • Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution

    NCT02325518 · start 2014-12

    Registered record
    Registry ID
    NCT02325518
    Conditions
    Open-Angle Glaucoma; Ocular Hypertension
    Interventions
    Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension; Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution; Subject's habitual PGA monotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-12
    Completion
    2015-12
    Enrolment
    218

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-Angle Glaucoma; Ocular Hypertension
    InterventionBrinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension; Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution; Subject's habitual PGA monotherapy
    PhasePhase 4
    Registry statusCompleted

  • A Study of Simbrinza™ Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension

    NCT02348476 · start 2014-11

    Registered record
    Registry ID
    NCT02348476
    Conditions
    Open-Angle Glaucoma; Ocular Hypertension
    Interventions
    No Intervention
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-11
    Completion
    2015-04
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-Angle Glaucoma; Ocular Hypertension
    InterventionNo Intervention
    PhaseNot recorded
    Registry statusCompleted

  • The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure

    NCT02165631 · start 2014-08

    Registered record
    Registry ID
    NCT02165631
    Conditions
    Open Angle Glaucoma; Ocular Hypertension; Pigment Dispersion Syndrome; Pseudoexfoliation Glaucoma
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-08
    Completion
    2016-03
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen Angle Glaucoma; Ocular Hypertension; Pigment Dispersion Syndrome; Pseudoexfoliation Glaucoma
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®

    NCT01937299 · start 2013-10

    Registered record
    Registry ID
    NCT01937299
    Conditions
    Ocular Hypertension; Open Angle Glaucoma
    Interventions
    Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension; Vehicle; Travoprost 0.004% ophthalmic solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-10
    Completion
    2014-04
    Enrolment
    307

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Hypertension; Open Angle Glaucoma
    InterventionBrinzolamide 1%/brimonidine 0.2% ophthalmic suspension; Vehicle; Travoprost 0.004% ophthalmic solution
    PhasePhase 4
    Registry statusCompleted

  • Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue

    NCT01937312 · start 2013-10

    Registered record
    Registry ID
    NCT01937312
    Conditions
    Ocular Hypertension; Open Angle Glaucoma
    Interventions
    Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension; Vehicle; Prostaglandin analogue
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-10
    Completion
    2014-05
    Enrolment
    282

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Hypertension; Open Angle Glaucoma
    InterventionBrinzolamide 1%/brimonidine 0.2% ophthalmic suspension; Vehicle; Prostaglandin analogue
    PhasePhase 4
    Registry statusCompleted

  • Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension

    NCT01978600 · start 2013-10

    Registered record
    Registry ID
    NCT01978600
    Conditions
    Open-Angle Glaucoma; Ocular Hypertension
    Interventions
    Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension; Timolol Maleate 0.5%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-10
    Completion
    2014-03
    Enrolment
    89

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-Angle Glaucoma; Ocular Hypertension
    InterventionBrinzolamide 1%/Brimonidine 0.2% ophthalmic suspension; Timolol Maleate 0.5%
    PhasePhase 4
    Registry statusCompleted

  • Latanoprost/Brinzolamide BID Versus Latanoprost BID in Patients With OAG or OH

    NCT01721707 · start 2012-12

    Registered record
    Registry ID
    NCT01721707
    Conditions
    Open Angle Glaucoma; Ocular Hypertension
    Interventions
    Latanoprost+Brinzolamide combination; Latanoprost
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2012-12
    Completion
    2013-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen Angle Glaucoma; Ocular Hypertension
    InterventionLatanoprost+Brinzolamide combination; Latanoprost
    PhasePhase 3
    Registry statusWithdrawn

  • Clinical Evaluation of Patients With X-linked Retinoschisis

    NCT02331173 · start 2012-11

    Registered record
    Registry ID
    NCT02331173
    Conditions
    X-linked Retinoschisis; XLRS
    Interventions
    Dorzolamide 2% TID or brinzolamide 1% TID
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-11
    Completion
    2016-10
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionX-linked Retinoschisis; XLRS
    InterventionDorzolamide 2% TID or brinzolamide 1% TID
    PhaseNot recorded
    Registry statusCompleted

  • Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves

    NCT01535768 · start 2012-02

    Registered record
    Registry ID
    NCT01535768
    Conditions
    Glaucoma
    Interventions
    Aqueous Suppressant Eye Drops
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2012-02
    Completion
    2020-06
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionAqueous Suppressant Eye Drops
    PhasePhase 4
    Registry statusUnknown

  • Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America

    NCT01518244 · start 2011-12

    Registered record
    Registry ID
    NCT01518244
    Conditions
    Glaucoma
    Interventions
    Brinzolamide/timolol maleate fixed combination
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-12
    Completion
    2013-02
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionBrinzolamide/timolol maleate fixed combination
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada

    NCT01415401 · start 2011-09

    Registered record
    Registry ID
    NCT01415401
    Conditions
    Glaucoma; Ocular Hypertension; Open-angle Glaucoma
    Interventions
    Brinzolamide 1% / timolol 0.5% maleate fixed combination
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-09
    Completion
    2013-06
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma; Ocular Hypertension; Open-angle Glaucoma
    InterventionBrinzolamide 1% / timolol 0.5% maleate fixed combination
    PhasePhase 4
    Registry statusCompleted

  • Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension

    NCT01310777 · start 2011-05

    Registered record
    Registry ID
    NCT01310777
    Conditions
    Open-Angle Glaucoma; Ocular Hypertension
    Interventions
    Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension; Brinzolamide 1% ophthalmic suspension; Brimonidine tartrate 0.2% ophthalmic solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-05
    Completion
    2013-01
    Enrolment
    771

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-Angle Glaucoma; Ocular Hypertension
    InterventionBrinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension; Brinzolamide 1% ophthalmic suspension; Brimonidine tartrate 0.2% ophthalmic solution
    PhasePhase 3
    Registry statusCompleted